Mammoscintigraphy in Patients with Aggressive Biological Subtypes of Breast Cancer: Assessment of Response to Neoadjuvant Chemotherapy
- 28 March 2026
- journal article
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (1)
Abstract
Purpose : To determine the diagnostic performance of mammoscintigraphy (SMG) with the 99m Tc-methoxy-isobutyl-isonitrile ( 99m Tc-MIBI) when used for assessment of the response to neoadjuvant chemotherapy (NACT) in patients with triple-negative and HER2-positive breast cancer (BC). Materials and methods : This retrospective study included 93 patients with morphologically verified triple-negative and HER2-positive breast cancer who received NACT between 2011 and 2018. Mammoscintigraphy was performed before treatment, after 2–3 and/or after 4–6 cycles of NACT. Diagnostic conclusions of SMG were compared with the results of morphological examination after surgical treatment at the end of NACT. The degree of pathological response to NACT was evaluated according to the Miller-Payne classification. Results : Overall, the sensitivity and specificity of SMG in predicting of complete pathologic tumor response after the completion of NACT were 83 % and 92 %, respectively. In patients with triple-negative and HER2-positive BC, sensitivity and specificity were 87 % and 92 %; 78 % and 91 %, respectively. When a complete scintigraphic response (grade V) was achieved after 2–3 cycles of NACT, the specificity and positive predictive value of SMG reached 100 % for both aggressive BC subtypes. Conclusions : The obtained results indicate the high diagnostic potential of SMG in predicting complete pathological tumor response to the NACT. Exceptional specificity and positive predictive value of SMG in the middle of the NACT make it promising tool in selection of BC patients for surgery de-escalation/elimination.Keywords
This publication has 20 references indexed in Scilit:
- Selective Elimination of Breast Surgery for Invasive Breast CancerJAMA Oncology, 2025
- Accuracy of Post–Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual CancerJAMA Surgery, 2020
- Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast CancerJAMA Oncology, 2020
- Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patientsThe Breast, 2018
- Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and ShortcomingsClinical Breast Cancer, 2018
- Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?European Journal of Cancer, 2016
- Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular SubtypesClinical Breast Cancer, 2016
- Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2014
- Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Monitoring the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Meta–AnalysisClinical Breast Cancer, 2013
- Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammographyCancer, 1999